Generic versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) have arrived, but a closer look at which competitor might win the coveted 180-day exclusivity ...

Teva Pharmaceutical must face a lawsuit claiming it used unlawful methods to block generic competition for its multiple ...

Teva Pharmaceuticals Industries Ltd. dodged some claims and will continue to litigate others in multidistrict litigation brought by drug wholesalers and retailers, as well as a suit brought by a rival ...

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

Roche (RHHBF) (RHHBY) has announced plans to seek regulatory review for an experimental therapy for multiple sclerosis, an autoimmune condition affecting the central nervous system, even as its ...

Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...